Together, these results suggested that treatment with NTX, PRO, and NTX + PRO downregulated the expression of cyclin B1, CDK1, and the phosphorylation of CDK1, which caused G2/M phase cell cycle arrest without displaying sub-G1 populations in all the breast cancer cells. The gene discussed is CCNB1; the disease is breast carcinoma.